Actuate Therapeutics Inc (ACTU) Stock Price & Analysis
Actuate Therapeutics Inc (ACTU) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.2138 (-12.95%), as of the Nov 19, 2026 trading session; market cap $12.9M.
Educational signal · not a buy or sell recommendation · How to read this
Actuate Therapeutics Inc · ACTU · NASDAQ
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Their lead product, Elraglusib Injection, targets metastatic pancreatic ductal adenocarcinoma and other cancers.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Actuate Therapeutics (ACTU)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Falling.
Earnings yield is the main valuation drag relative to sector peers.
- EPS beat 4 of the last 8 reports
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 26 | Weak | |
| 26 | Weak | |
| 27 | Weak | |
| 27 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.2138 | |
| Change on the day | -12.95% | |
| 52-week range | $0.2138 – $7.90 | |
| Market capitalisation | $12.9M | — |
| Shares traded on the day | 2.99M |
Price & events
Other perspectives
Council score for Actuate Therapeutics (ACTU): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Actuate Therapeutics (ACTU), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Actuate Therapeutics Inc (ACTU) is listed on NASDAQ. It employs 12 people and is led by Daniel Schmitt. The market values it at $12.9M.
What do the latest results show for Actuate Therapeutics (ACTU)?
Short answer · as of
Against analyst estimates the company has EPS beat 4 of the last 8 reports.
What are the financial strengths and risks for Actuate Therapeutics (ACTU)?
Short answer · as of
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.73.
Data-derived red flags
- Listing risk — at $0.2138 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Actuate Therapeutics (ACTU)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -0.64 · 0 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for ACTU.
Checked against the records this page reads, on the dates shown above.
How does Actuate Therapeutics compare with its peers?
Short answer
Actuate Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $58.34 Nov 19, 2026 | $119B | 85 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $168.98 Nov 18, 2026 | $210B | 72 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $137.78 Nov 18, 2026 | $340B | 69 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| Actuate Therapeutics (ACTU) — this page | $0.2138 | $12.9M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $0.00
- EPS estimate
- $-0.64
Measured against a quoted price of $0.2138 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 28, 2026
- Transactions
- 35
- Identified insiders
- 4
- Purchases
- 2
- Sales
- 0
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ACTU in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACTU in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Actuate Therapeutics (ACTU)?
- Actuate Therapeutics Presents Preclinical Data for Elraglusib in Melanoma Models
- Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
- Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
- Actuate Therapeutics Says U.S. Patent Office Allowed Application Covering Oral Elraglusib Tablet, Ahead Of Phase 1/2 Trial In Q1 2027
Actuate Therapeutics Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ACTU research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ACTU?
ACTU carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment.
Is ACTU a good stock to buy?
Stock Expert AI does not rate ACTU buy, sell or hold. Actuate Therapeutics Inc carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACTU stock price today?
The last price recorded for Actuate Therapeutics Inc (ACTU), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ACTU?
Actuate Therapeutics faces several key risks inherent to its business model and industry. The primary risk is the potential failure of Elraglusib in clinical trials, which would significantly impact the company's value.
What are the key factors to evaluate for ACTU?
Actuate Therapeutics Inc (ACTU) holds a MoonshotScore in the low range. This strategy could be implemented at any time, depending on clinical trial progress and market interest. Not financial advice.
How frequently does ACTU data refresh on this page?
ACTU's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACTU's recent stock price performance?
Actuate Therapeutics Inc (ACTU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACTU overvalued or undervalued right now?
Actuate Therapeutics Inc (ACTU) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ACTU?
Fractional-share availability for Actuate Therapeutics Inc (ACTU) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 5 from Financial Modeling Prep (FMP), 10 with no recorded source and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com